309P - Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): From randomized trials to real-life setting: Results from GIM13 - AMBRA study

Abstract

Background: Two randomized studies demonstrated that Nab-P produces a significantly higher overall response rate (ORR), longer Time to Progression (TTP), and greater overall survival (OS) in ABC pts treated with second-line or greater therapy compared with patients who receive conventional Paclitaxel. However, few data are available in the real-life setting, especially for the weekly schedule (wNab-P). Methods: AMBRA is a longitudinal cohort study, aiming to describe the choice of first and subsequent lines of treatment in HER2-ve ABC pts receiving at least one CHT (SABCS 2016, P5-15-07 & P5-14-09) in the years 2012-2015. For the present analysis, we focused on the use of Nab-P, describing efficacy results according to pts’ characteristics. Results: So far, 791/1500 pts have been registered into the study and 107 (13.5%) received Nab-P in any line of treatment. Median age was 54 years, 88 (82.2%) had Luminal tumours. Twenty-two pts (20.6%) received Nab-P as 1st line, 48 (44.8%) as 2nd-line, the remaining as 3rd-line or greater. Most pts (47.7%) received the every 3 weeks (Q21) schedule, whereas 30 pts (28%) were treated with the weekly (wNab-P) schedule (days 1,8,15 Q28) at different doses: £100 mg/mq: 11 (10.3%), 125 mg/mq,: 15 (14%); 150 mg/mq: 4 (3.7%). The remaining received different schedules or doses. Median number of cycles received was 5 (1-17) and median duration of treatment was 3.5 months in the whole population. No difference has been observed in terms of number of cycles or duration of treatment according to the schedule. Conclusions: Our results are similar to those obtained in randomized clinical trials and in a recent large real-life study, confirming that Nab-P is currently one of the most promising choice of treatment for ABC pts. Legal entity responsible for the study: Marina Elena Cazzaniga Funding: GIM - Gruppo Italiano Mammella Disclosure: All authors have declared no conflicts of interest.